Medis™

Medis™ is a precision intelligence platform engineered to solve the "data scarcity" problem in pediatric oncology. By leveraging advanced AI architectures, it transforms fragmented, global research into actionable clinical insights.

Medis™ operates as a sophisticated analytical layer that sits atop existing medical data infrastructures to accelerate the path to a cure.

• Federated Data Synthesis: It utilizes Federated Learning to analyze sensitive patient data across multiple international institutions simultaneously. This allows the AI to "learn" from a global pool of rare cancer cases without the raw data ever leaving its secure home facility.
• Multi-Omic Pattern Recognition: The platform integrates diverse biological datasets—including genomics, proteomics, and transcriptomics—to create a high-definition molecular map of pediatric tumors.
• Predictive Outcomes Modeling: Artemis™ calculates the Probability of Progression ($P_p$) and treatment response by identifying "molecular twins" across historical data, helping clinicians move beyond "one-size-fits-all" protocols.
• Precision Trial Matching: It autonomously scans global clinical trial registries to match pediatric patients with experimental therapies based on their specific genetic drivers, significantly reducing the time from diagnosis to enrollment.

Medis™ is designed for the high-level stakeholders driving the future of precision medicine.

• Pediatric Oncologists & Clinicians: Provides a "super-powered" second opinion at the bedside, offering data-backed insights into rare mutations and targeted therapy options.
• Research Institutions & Bioinformaticians: Serves as a force-multiplier for discovery, allowing researchers to find patterns in "small N" (rare) datasets that were previously statistically invisible.
• Federal Agencies (NIH/NCI): Acts as the critical infrastructure for national initiatives (like the CCDI) to harmonize data and meet federal mandates for AI-driven healthcare innovation.
• Strategic Payors & CMS: Enables a shift toward Value-Based Care by predicting which high-cost therapies are most likely to be effective, thereby reducing waste and improving long-term survivorship metrics.
• Biopharmaceutical Developers: Accelerates the R&D pipeline for pediatric-specific orphan drugs by identifying viable patient cohorts for specialized clinical trials.